Profiling of early-onset bladder cancer identifies key genomic alterations and potential targets.

Christopher J. Magnani[1], Vincent D. D'Andrea[1], Zhiyu Qian[1], John Ernandez[1], Kendrick Yim[1], Adam S. Kibel[1], Steven L. Chang[1], Matthew Mossanen[1], Mark A. Preston[1], Adam S. Feldman[2], Bernard H. Bochner[3], David B. Solit[3], Eugene J. Pietzak[3], Kent W. Mouw[1], Filipe L.F. Carvalho[1,†], Timothy N. Clinton[1,†]

[†] Equal study contribution as co-principal investigators.

1. Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

2. Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

3. Memorial Sloan Kettering Cancer Center, New York, New York

Abstract:

Younger patients with bladder cancer typically have fewer environmental exposures or risk factors, suggesting molecular pathways implicated in early-onset disease differ from older patients. Dissecting the genomic profile of early-onset tumors may define targeted treatments for these young patients. We compared the frequency of somatic mutations in early-onset bladder cancer, defined as diagnosis before the age of 55 years old which encompasses about 1 in 10 diagnoses, in two cohorts: the Mass General Brigham Young Cystectomy Cohort (MGB-YCC, n=134 patients) and the Memorial Sloan-Kettering-IMPACT bladder cancer cohort (MSK-IMPACT, n=1271). Both MGB-YCC and MSK-IMPACT cohorts were predominantly male with younger patients less likely to smoke or have muscle-invasive disease. Genomic characterization in MGB-YCC demonstrated KMT2D mutations almost exclusively among the youngest patients (83% <45-years-old, p=0.008). MSK-IMPACT revealed a significant increase of FGFR3 mutations in younger patients (37% vs 23%, p<0.001). Altogether, our results find key somatic mutations likely drive early-onset bladder cancers, some of which may be targetable; this suggests potential benefit from genomic tumor profiling to guide personalized treatment.

Key Words: Bladder Cancer, Early-Onset, Genomics, Next-Generation Sequencing, Translational

Abbreviations

FDA: Food and Drug Administration
MGB-YCC: Mass General Brigham Young Cystectomy Cohort
MSK-IMPACT: Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets
NCI: National Cancer Institute
NSQIP: National Surgical Quality Improvement Program
RC: Radical Cystectomy

Source of Funding: NCI K08CA282969-01A1 (FLC), BCAN Career Development Award (FLC), NCI 3P30CA006516-59W2 Early-Stage Surgeon-Scientist Program award (FLC).

Disclosures or conflicts: none

Manuscript:

Significant advances have been made in the genomic characterization of primary and metastatic urothelial carcinoma[1,2]. There are well-established environmental and life-style risk factors such as tobacco or other chemical carcinogen exposures[3], and older patients accumulate mutations that drive oncogenesis and tumor progression in addition to providing opportunities for certain targeted therapeutic strategies[4]. The median age of diagnosis for bladder cancer patients is 73 years, and more than 90% of patients are over age 55 at diagnosis[5].

No consensus criteria for early-onset bladder cancer exists; therefore, we used a definition of diagnosis before age 55 and selected this cut off to capture the youngest 10% of patients with newly diagnosed bladder cancers[5]. Because younger patients typically have less exposure to risk factors, we hypothesized that molecular pathways driving early-onset disease are distinct from those in older patients and likely rely on earlier acquisition of key driving mutations. Prior studies have also suggested bladder cancers diagnosed earlier in life are more aggressive, with patients more likely to have multiple metastatic sites and a greater propensity for metastases beyond lymph nodes to the brain and liver[6]. However, genomic characterization of these early-onset bladder tumors are limited to date. By defining the molecular features of bladder tumors arising in young patients, new treatment approaches may be identified. Our goal in this study was to define clinically relevant genomic features of early-onset bladder cancer and nominate potentially targetable somatic mutations.

Using two institutional databases, we identified a retrospective cohort of 134 patients undergoing radical cystectomy (RC) with curative intent from 2008-2023 for a bladder cancer primary before age 55 (Mass General Brigham Young Cystectomy Cohort, MGB-YCC), including a cohort of 17 patients with targeted next-generation tumor sequencing (OncoPanel[7]). Manual review was performed to confirm diagnosis and obtain clinical outcomes, which were compared to published[8] NSQIP (National Surgical Quality Improvement Program) data of 10,848 patients undergoing RC between 2008-2013 (Supplement). We also compared the MGB-YCC patients to 1,271 bladder cancer patients who underwent targeted tumor sequencing with MSK-IMPACT[2] (which includes patient-matched tumor and blood for germline DNA samples) between 2014-2021, including 212 (16.7%) diagnosed before age 55. Chi-square and Kruskal-Wallis tests were performed, and all analyses were performed with R version 4.3.2 (R Foundation for Statistical Computing, Vienna, Austria) with $p<0.05$ considered statistically significant for all tests.

Patients with early-onset bladder cancer (age <55) in both MGB-YCC and MSK-IMPACT cohorts were predominantly male (84% and 76%, respectively), had similar rates of muscle-invasive (≥T2) disease (57% and 54%), and smoking (55% and 53%, Tables 1, S1-S2). Young patients with early-onset disease in MSK-IMPACT compared to those over age 55 had a similar proportion of male patients (76% vs 77%, p 0.6), fewer smokers (53% vs 67%, $p<0.001$), and more low-grade tumors (10% vs 4%, p 0.001, Tables 1, S1). Genomic characterization of MGB-YCC (Table 1, Figure S1) demonstrated mutations in *TP53* (65%) and *KMT2D* (35%) were more frequently mutated as patient age decreased (p 0.045 and p 0.008, respectively, Table S2). In MSK-IMPACT, there was a significant increase in FGFR3 mutations in younger patients (37% vs 23%, $p<0.001$) and lower mutation rates of *TERT* (68% vs 75%, $p<0.044$), *TP53* (40% vs 50%, $p<0.013$), and *RB1* (12% vs 21%, $p<0.007$) (Table 1). These relationships are shown in Figure 1, which emphasizes the enrichment in the MGB-YCC and MSK-IMPACT cohorts of *KMT2D* and *FGFR3*.

Young patients with early-onset bladder cancer (diagnosis before age 55) represent a clinically distinct population that presents with more aggressive disease[6]. Thus, we sought to identify potential genomic features explaining a distinct biological behavior in early-onset bladder cancer. Younger patients are less likely to smoke and have had less time to accumulate exposure to risk factors. This suggests early-onset tumors likely follow molecular pathways diverging from those thought to drive bladder cancer in older patients, potentially with acquisition of driving mutations earlier in the course of their disease. Moreover, we demonstrate that younger patients have significantly higher rates of potentially actionable mutations such as *KMT2D*, a methyltransferase with inhibitors in development in several tumor types[9], and *FGFR3*, a tyrosine kinase that can be targeted with erdatifinib which is FDA-approved in bladder cancer[10]. Demonstration of potentially targetable mutations suggests benefit for young patients with early-onset bladder cancer to undergo tumor sequencing to guide systemic treatment.

Our study is limited to two cohorts of patients treated in academic institutions; however, this is the largest analysis to date to define genomic features of early-onset bladder cancer. This study provides a first step towards defining the genomic landscape of early onset bladder cancer, and by increasing next generation sequencing efforts across different institutions future studies will further advance our understanding. Greater interest in the scientific and urologic community in sequencing early-onset tumors will better characterize the genomic landscape of early-onset bladder cancer, identify recurrent and actionable somatic alterations with greater confidence, and improve personalized treatment by ultimately yielding treatment strategies and specific clinical trials for this subgroup of young bladder cancer patients.

	MGB-YCC	MSK-IMPACT			
Age	**Overall**	**Overall**	**< 55**	**≥ 55**	**p**
N (%)	**134 (100.0)**	1271 (100.0)	**212 (16.7)**	1059 (83.3)	
Age, mean (SD)	**47.30 (5.90)**	65.22 (11.12)	**47.16 (6.94)**	68.84 (7.77)	<0.001
Male (%)	**113 (84.3)**	980 (77.1)	**160 (75.5)**	820 (77.4)	0.6
Smoking (%)	**73 (54.5)**	813 (64.7)	**111 (53.1)**	702 (67.0)	<0.001
Stage ≥T2 (%)	**76 (56.7)**	777 (61.1)	**115 (54.2)**	662 (62.5)	0.03
Highlighted Mutations					
TERT	**4 (23.5)**	937 (73.7)	**144 (67.9)**	793 (74.9)	0.044
TP53	**11 (64.7)**	612 (48.2)	**85 (40.1)**	527 (49.8)	0.013
FGFR3	**1 (5.9)**	319 (25.1)	**78 (36.8)**	241 (22.8)	<0.001
KDM6A	**4 (23.5)**	332 (26.1)	**52 (24.5)**	280 (26.4)	0.6
PIK3CA	**3 (17.6)**	236 (18.6)	**46 (21.7)**	190 (17.9)	0.2
CDKN2A	**1 (5.9)**	285 (22.4)	**41 (19.3)**	244 (23.0)	0.3
ARID1A	**4 (23.5)**	299 (23.5)	**39 (18.4)**	260 (24.6)	0.06
CDKN2B	**0 (0.0)**	218 (17.2)	**36 (17.0)**	182 (17.2)	>0.9
KMT2D	**6 (35.3)**	235 (18.5)	**31 (14.6)**	204 (19.3)	0.1
CDKN1A	**2 (11.8)**	150 (11.8)	**27 (12.7)**	123 (11.6)	0.7
RB1	**4 (23.5)**	243 (19.1)	**26 (12.3)**	217 (20.5)	0.007
CCND1	**0 (0.0)**	139 (10.9)	**26 (12.3)**	113 (10.7)	0.6
ERBB2	**0 (0.0)**	192 (15.1)	**24 (11.3)**	168 (15.9)	0.1
STAG2	**1 (5.9)**	123 (9.7)	**23 (10.8)**	100 (9.4)	0.6
EP300	**0 (0.0)**	92 (7.2)	**19 (9.0)**	73 (6.9)	0.4

Table 1: Assessing Characteristics of Patients with Early-Onset Bladder Cancer

Comparison of genomic mutation profiles of Mass General Brigham Young Cystectomy Cohort (MGB-YCC) and Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) cohort. Early-onset bladder cancer defined as diagnosis before age 55. Final MGB-YCC cohort n=134 after excluding 44 patients undergoing Radical Cystectomy for non-bladder primary and excluding 4 patients undergoing palliative procedure; 17 patients with available OncoPanel data. MSK-IMPACT cohort n=1,271 after excluding 42 patients missing diagnostic age data. Additional characteristics provided in Tables S1-S2.



Figure 1: Gene Mutation Rates

Graphical representation of genomic mutation profiles of Mass General Brigham (MGB) and Memorial Sloan Kettering (MSK) cohorts, which demonstrate a significant age-dependent distribution also available in Table 1. Notably, KMT2D and FGFR3 are enriched in MGB-YCC and MSK-IMPACT cohorts, respectively.

References:

1. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network; Weinstein JN, Kwiatkowski DJ, Lerner SP. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5. Erratum in: Cell. 2018 Aug 9;174(4):1033. doi: 10.1016/j.cell.2018.07.036. PMID: 28988769; PMCID: PMC5687509.
2. Clinton TN, Chen Z, Wise H, Lenis AT, Chavan S, Donoghue MTA, Almassi N, Chu CE, Dason S, Rao P, Rodrigues JA, Vasani NB, Ridouani F, Rosenberg JE, Bajorin DF, Teo MY, Bochner BH, Berger MF, Ostrovnaya I, Pietzak EJ, Iyer G, Gao SP, Hu W, Al-Ahmadie HA, Solit DB. Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Rep. 2022 Dec 20;41(12):111859. doi: 10.1016/j.celrep.2022.111859. PMID: 36543146; PMCID: PMC9882421.
3. Beatrici E, Labban M, Filipas DK, Stone BV, Reis LO, Dagnino F, Lughezzani G, Buffi NM, Lipsitz SR, Clinton TN, Matulewicz RS, Trinh QD, Cole AP. Smoking characteristics and years since quitting smoking of US adults diagnosed with lung and bladder cancer: A national health and nutrition examination survey analysis. Int Braz J Urol. 2024 Mar-Apr;50(2):199-208. doi: 10.1590/S1677-5538.IBJU.2023.0625. PMID: 38386790; PMCID: PMC10953605.
4. D'Andrea VD, Magnani CJ, Ernandez J, Bellmunt J, Mossanen M, Clinton TN, Carvalho FLF, Mouw KW. Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer. Curr Urol Rep. 2024 Oct 9;26(1):12. doi: 10.1007/s11934-024-01242-4. PMID: 39382743.
5. Surveillance Research Program, National Cancer Institute; 2024 Apr 17. [updated: 2024 Nov 5; cited 2024 Dec 2]. Available from: https://seer.cancer.gov/statistics-network/explorer/. Data source(s): SEER Incidence Data, November 2023 Submission (1975-2021), SEER 22 registries.
6. Bianchi M, Roghmann F, Becker A, Sukumar S, Briganti A, Menon M, Karakiewicz PI, Sun M, Noldus J, Trinh QD. Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. Can Urol Assoc J. 2014 Mar-Apr;8(3-4):E148-58. doi: 10.5489/cuaj.787. PMID: 24678354; PMCID: PMC3956834.
7. Garcia EP, Minkovsky A, Jia Y, Ducar MD, Shivdasani P, Gong X, Ligon AH, Sholl LM, Kuo FC, MacConaill LE, Lindeman NI, Dong F. Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. Arch Pathol Lab Med. 2017 Jun;141(6):751-758. doi: 10.5858/arpa.2016-0527-OA. Epub 2017 Mar 3. PMID: 28557599.
8. Reese SW, Ji E, Paciotti M, Leow JJ, Mahvi DA, Steele G, Urman RD, Whang EE, Kibel AS, Mossanen M. Risk factors and reasons for reoperation after radical cystectomy. Urol Oncol. 2020 Apr;38(4):269-277. doi: 10.1016/j.urolonc.2019.10.011. Epub 2019 Nov 22. PMID: 31761610.
9. Rao RC, Dou Y. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer. 2015 Jun;15(6):334-46. doi: 10.1038/nrc3929. PMID: 25998713; PMCID: PMC4493861.
10. Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. PMID: 37870920.

Profiling of early-onset bladder cancer identifies key genomic alterations and potential targets.

Christopher J. Magnani[1], Vincent D. D'Andrea[1], Zhiyu Qian[1], John Ernandez[1], Kendrick Yim[1], Adam S. Kibel[1], Steven L. Chang[1], Matthew Mossanen[1], Mark A. Preston[1], Adam S. Feldman[2], Bernard H. Bochner[3], David B. Solit[3], Eugene J. Pietzak[3], Kent W. Mouw[1], Filipe L.F. Carvalho[1,†], Timothy N. Clinton[1,†]

[†] Equal study contribution as co-principal investigators.

1. Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

2. Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

3. Memorial Sloan Kettering Cancer Center, New York, New York

Supplemental Information

- **Table S1: MSK-IMPACT Cohort Characteristics**
- **Table S2: MGB-YCC Characteristics**
- **Table S3: Post-Operative Complications - Institutional vs National Cohorts**
- **Figure S1: Oncoplot, MGB Young Cystectomy Cohort**

Table S1: MSK IMPACT Cohort Characteristics

Age	Overall	< 55	≥ 55	p	< 45	45 - 49	50 - 54	p
N (%)	1271 (100.0)	212 (16.7)	1059 (83.3)		60 (28.3)	56 (26.4)	96 (45.3)	
Age, mean (SD)	65.22 (11.12)	47.16 (6.94)	68.84 (7.77)	<0.001	37.75 (5.22)	47.77 (1.48)	52.67 (1.38)	<0.001
Age, median [IQR]	66.4 [58.4, 73.2]	49.2 [43.4, 52.3]	68.40 [62.40, 74.60]	<0.001	38.2 [34.6, 42.5]	48.1 [46.7, 49.0]	52.8 [51.9, 53.7]	<0.001
Male (%)	980 (77.1)	160 (75.5)	820 (77.4)	0.6	45 (75.0)	48 (85.7)	67 (69.8)	0.08
Smoking (%)	813 (64.7)	111 (53.1)	702 (67.0)	<0.001	22 (36.7)	28 (51.9)	61 (64.2)	0.004
Stage ≥T2, Muscle Invasive (%)	777 (61.1)	115 (54.2)	662 (62.5)	0.03	28 (46.7)	27 (48.2)	60 (62.5)	0.09
Intravesical Treatment (%)				0.3				0.8
None	891 (70.2)	142 (67.3)	749 (70.8)		44 (73.3)	37 (66.1)	61 (64.2)	
BCG	257 (20.3)	46 (21.8)	211 (19.9)		11 (18.3)	14 (25.0)	21 (22.1)	
Chemo	30 (2.4)	3 (1.4)	27 (2.6)		1 (1.7)	0 (0.0)	2 (2.1)	
Both	91 (7.2)	20 (9.5)	71 (6.7)		4 (6.7)	5 (8.9)	11 (11.6)	
Systemic Treatment (%)				0.2				
None	996 (78.9)	164 (78.5)	832 (79.0)		50 (83.3)	39 (72.2)	75 (78.9)	
Chemo	220 (17.4)	42 (20.1)	178 (16.9)		9 (15.0)	13 (24.1)	20 (21.1)	
Immunotherapy	16 (1.3)	0 (0.0)	16 (1.5)		0 (0.0)	0 (0.0)	0 (0.0)	
Both	30 (2.4)	3 (1.4)	27 (2.6)		1 (1.7)	2 (3.7)	0 (0.0)	
Specimen Stage (%)				0.001				0.01
Low Grade	69 (5.4)	22 (10.4)	47 (4.4)		12 (20.0)	5 (8.9)	5 (5.2)	
High Grade, Non-Invasive	234 (18.4)	48 (22.6)	186 (17.6)		11 (18.3)	18 (32.1)	19 (19.8)	
High Grade, Invasive	737 (58.0)	105 (49.5)	632 (59.7)		32 (53.3)	22 (39.3)	51 (53.1)	
Metastatic	231 (18.2)	37 (17.5)	194 (18.3)		5 (8.3)	11 (19.6)	21 (21.9)	
Specimen Type (%)				0.08				
Cystectomy	207 (16.3)	27 (12.7)	180 (17.0)		3 (5.0)	8 (14.3)	16 (16.7)	
Metastasis	231 (18.2)	37 (17.5)	194 (18.3)		5 (8.3)	11 (19.6)	21 (21.9)	
Partial Cystectomy	14 (1.1)	2 (0.9)	12 (1.1)		0 (0.0)	1 (1.8)	1 (1.0)	
TUR	811 (63.8)	143 (67.5)	668 (63.1)		51 (85.0)	36 (64.3)	56 (58.3)	
Urethral biopsy	3 (0.2)	0 (0.0)	3 (0.3)		0 (0.0)	0 (0.0)	0 (0.0)	
Urethrectomy	5 (0.4)	3 (1.4)	2 (0.2)		1 (1.7)	0 (0.0)	2 (2.1)	
Stage (%)				0.006				0.006
Low Grade	69 (5.4)	22 (10.4)	47 (4.4)		12 (20.0)	5 (8.9)	5 (5.2)	
High Grade	378 (29.7)	65 (30.7)	313 (29.6)		17 (28.3)	24 (42.9)	24 (25.0)	
CIS	47 (3.7)	10 (4.7)	37 (3.5)		3 (5.0)	0 (0.0)	7 (7.3)	
Muscle-Invasive	546 (43.0)	78 (36.8)	468 (44.2)		23 (38.3)	16 (28.6)	39 (40.6)	
Metastatic	231 (18.2)	37 (17.5)	194 (18.3)		5 (8.3)	11 (19.6)	21 (21.9)	
Histology (%)				0.3				0.4
Urothelial Carcinoma	936 (73.6)	167 (78.8)	769 (72.6)		50 (83.3)	49 (87.5)	68 (70.8)	
Squamous Cell	84 (6.6)	16 (7.5)	68 (6.4)		5 (8.3)	2 (3.6)	9 (9.4)	
Plasmacytoid	37 (2.9)	5 (2.4)	32 (3.0)		0 (0.0)	1 (1.8)	4 (4.2)	
Small Cell, Neuroendocrine	49 (3.9)	7 (3.3)	42 (4.0)		1 (1.7)	1 (1.8)	5 (5.2)	
Micropapillary	40 (3.1)	2 (0.9)	38 (3.6)		0 (0.0)	0 (0.0)	2 (2.1)	
Glandular	20 (1.6)	2 (0.9)	18 (1.7)		0 (0.0)	0 (0.0)	2 (2.1)	
Other	105 (8.3)	13 (6.1)	92 (8.7)		4 (6.7)	3 (5.4)	6 (6.2)	
Select Mutations (%)								
TERT	937 (73.7)	144 (67.9)	793 (74.9)	0.044	34 (56.7)	34 (60.7)	76 (79.2)	0.006
TP53	612 (48.2)	85 (40.1)	527 (49.8)	0.013	21 (35.0)	17 (30.4)	47 (49.0)	0.05
FGFR3	319 (25.1)	78 (36.8)	241 (22.8)	<0.001	26 (43.3)	21 (37.5)	31 (32.3)	0.4
KDM6A	332 (26.1)	52 (24.5)	280 (26.4)	0.6	14 (23.3)	13 (23.2)	25 (26.0)	0.9
PIK3CA	236 (18.6)	46 (21.7)	190 (17.9)	0.2	12 (20.0)	9 (16.1)	25 (26.0)	0.3
CDKN2A	285 (22.4)	41 (19.3)	244 (23.0)	0.3	9 (15.0)	12 (21.4)	20 (20.8)	0.6
ARID1A	299 (23.5)	39 (18.4)	260 (24.6)	0.07	13 (21.7)	7 (12.5)	19 (19.8)	0.4
CDKN2B	218 (17.2)	36 (17.0)	182 (17.2)	>0.9	9 (15.0)	9 (16.1)	18 (18.8)	0.8
KMT2D	235 (18.5)	31 (14.6)	204 (19.3)	0.1	10 (16.7)	5 (8.9)	16 (16.7)	0.4
CDKN1A	150 (11.8)	27 (12.7)	123 (11.6)	0.7	11 (18.3)	6 (10.7)	10 (10.4)	0.3
RB1	243 (19.1)	26 (12.3)	217 (20.5)	0.007	6 (10.0)	2 (3.6)	18 (18.8)	0.019
CCND1	139 (10.9)	26 (12.3)	113 (10.7)	0.6	7 (11.7)	9 (16.1)	10 (10.4)	0.6
ERBB2	192 (15.1)	24 (11.3)	168 (15.9)	0.1	5 (8.3)	3 (5.4)	16 (16.7)	0.07
STAG2	123 (9.7)	23 (10.8)	100 (9.4)	0.6	9 (15.0)	4 (7.1)	10 (10.4)	0.4
EP300	92 (7.2)	19 (9.0)	73 (6.9)	0.4	4 (6.7)	3 (5.4)	12 (12.5)	0.3

Table S2: MGB Young Cystectomy Cohort Characteristics

Age	Overall	< 45	45 - 49	50 - 54	p
N (%)	134 (100.0)	31 (23.1)	48 (35.8)	55 (41.0)	
Age, mean (SD)	47.30 (5.90)	38.94 (5.93)	47.35 (1.47)	51.96 (1.41)	<0.001
Age, median [IQR]	49 [45, 52]	41 [37, 43]	48 [46, 49]	52 [50.5, 53]	<0.001
Follow up - months, mean (SD)	59.06 (50.85)	68.40 (53.70)	45.94 (46.91)	65.24 (51.07)	0.08
Follow up - months, median [IQR]	45.8 [16.4, 89.1]	48.3 [25.2, 103.5]	25.4 [11.6, 68.4]	48.6 [25.7, 99.1]	0.04
BMI, mean (SD)	28.91 (5.99)	29.29 (6.48)	29.48 (6.11)	28.18 (5.61)	0.5
BMI, median [IQR]	28.6 [24.8, 32.0]	27.1 [24.9, 32.9]	29.8 [25.0, 32.2]	27.2 [24.1, 31.0]	0.5
Male (%)	113 (84.3)	25 (80.6)	42 (87.5)	46 (83.6)	0.7
Race = White (%)	129 (96.3)	28 (90.3)	48 (100.0)	53 (96.4)	0.09
Smoking (%)	73 (54.5)	15 (48.4)	25 (52.1)	33 (60.0)	0.5
Stage ≥T2, Muscle Invasive (%)	76 (56.7)	15 (48.4)	34 (70.8)	27 (49.1)	0.048
Ileal Conduit (%)	65 (48.5)	13 (41.9)	22 (45.8)	30 (54.5)	0.5
Robotic (%)	12 (9.0)	3 (9.7)	6 (12.5)	3 (5.5)	0.5
Neoadjuvant Chemo (%)	75 (56.0)	16 (51.6)	26 (54.2)	33 (60.0)	0.7
Neoadjuvant Chemo Response (%)	41 (54.7)	8 (50.0)	14 (53.8)	19 (57.6)	0.9
Length of stay - days, mean (SD)	8.10 (6.04)	7.68 (4.76)	8.21 (5.78)	8.25 (6.92)	0.9
Length of Stay - days, median [IQR]	7 [5.25, 8]	7 [6, 7.5]	6.5 [5, 8]	7 [6, 8]	>0.9
Operative time - hours, mean (SD)	7.90 (2.26)	8.17 (2.26)	8.31 (2.18)	7.27 (2.27)	0.1
Operative time - hours, median [IQR]	8.12 [5.89, 9.63]	8.17 [6.43, 9.95]	8.37 [6.56, 9.67]	6.90 [5.47, 9.04]	0.1
Intravesical Treatment (%)					0.3
None	96 (71.6)	22 (71.0)	34 (70.8)	40 (72.7)	
BCG	23 (17.2)	8 (25.8)	9 (18.8)	6 (10.9)	
Chemo	8 (6.0)	0 (0.0)	2 (4.2)	6 (10.9)	
Both	7 (5.2)	1 (3.2)	3 (6.2)	3 (5.5)	
Systemic Treatment (%)					0.8
None	49 (36.6)	13 (41.9)	17 (35.4)	19 (34.5)	
Chemo	73 (54.5)	15 (48.4)	26 (54.2)	32 (58.2)	
Immunotherapy	1 (0.7)	0 (0.0)	0 (0.0)	1 (1.8)	
Both	11 (8.2)	3 (9.7)	5 (10.4)	3 (5.5)	
Complication (30 day)					
Readmission (%)	50 (37.3)	11 (35.5)	19 (39.6)	20 (36.4)	0.9
Ileus (%)	23 (17.2)	3 (9.7)	9 (18.8)	11 (20.0)	0.4
Post-operative Transfusion (%)	28 (20.9)	8 (25.8)	13 (27.1)	7 (12.7)	0.2
DVT/PE (%)	12 (9.0)	4 (12.9)	3 (6.2)	5 (9.1)	0.6
Reoperation (%)	9 (6.7)	2 (6.5)	5 (10.4)	2 (3.6)	0.4
Pathology, T Stage (%)					0.6
T0	27 (20.1)	8 (25.8)	6 (12.5)	13 (23.6)	
Ta	8 (6.0)	2 (6.5)	3 (6.2)	3 (5.5)	
Tis	8 (6.0)	1 (3.2)	2 (4.2)	5 (9.1)	
T1	15 (11.2)	5 (16.1)	3 (6.2)	7 (12.7)	
T2	31 (23.1)	4 (12.9)	15 (31.2)	12 (21.8)	
T3	33 (24.6)	9 (29.0)	14 (29.2)	10 (18.2)	
T4	12 (9.0)	2 (6.5)	5 (10.4)	5 (9.1)	
Select Mutations (%)					
Matched Oncopanel (%)	17 (12.7)	6 (19.4)	6 (12.5)	5 (9.1)	0.4
TERT	4 (23.5)	1 (16.7)	2 (33.3)	1 (20.0)	0.8
TP53	11 (64.7)	5 (83.3)	5 (83.3)	1 (20.0)	0.045
FGFR3	1 (5.9)	0 (0.0)	0 (0.0)	1 (20.0)	0.3
KDM6A	4 (23.5)	0 (0.0)	2 (33.3)	2 (40.0)	0.2
PIK3CA	3 (17.6)	3 (50.0)	0 (0.0)	0 (0.0)	0.035
CDKN2A	1 (5.9)	0 (0.0)	1 (16.7)	0 (0.0)	0.4
ARID1A	4 (23.5)	2 (33.3)	1 (16.7)	1 (20.0)	0.8
CDKN2B	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	NA
KMT2D	6 (35.3)	5 (83.3)	1 (16.7)	0 (0.0)	0.008
CDKN1A	2 (11.8)	1 (16.7)	0 (0.0)	1 (20.0)	0.5
RB1	4 (23.5)	1 (16.7)	2 (33.3)	1 (20.0)	0.8
CCND1	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	NA
ERBB2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	NA
STAG2	1 (5.9)	0 (0.0)	1 (16.7)	0 (0.0)	0.4
EP300	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	NA

Table S3: Post-Operative Complications - Institutional vs National Cohorts

	MGB Young Cystectomy Cohort (2008-2023)	NSQIP* (2008-2023)
	Age <55	**All Ages**
N	134	10,848
Age, mean (SD)	47.30 (5.90)	69 (10.52)
Male (%)	113 (84.3)	8,289 (76.4)
Smoking (%)	73 (54.5)	8,310 (76.6)
Ileal Conduit (%)	65 (48.5)	9,228 (85.1)
Complication within 30 days (%)		
Readmission (%)	50 (37.3)	2,269 (20.9)
Ileus (%)	23 (17.2)	Not Available
Post-operative Transfusion (%)	28 (20.9)	4,100 (37.8)
DVT/PE (%)	12 (9.0)	299 (2.8)
Reoperation (%)	9 (6.7)	633 (5.8)

* = Reese *et al.* Urol Oncol. 2020 Apr;38(4):269-277. PMID: 31761610.

Figure S1: Oncoplot, MGB Young Cystectomy Cohort